Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis
Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis
复制标题
DOI：
10.1080/21678421.2018.1550516
复制
发表时间：
2019-01-02
影响因子：
2.8
通讯作者：
Shang, Huifang
中科院分区：
文献类型：
--
作者：
Chen, Xueping;Wei, Qian-Qian;Shang, Huifang
目的：肌萎缩侧索硬化（ALS）患者的临床分期是否会影响血清学指标尚不清楚。我们的目的是探讨血清学因素的水平与国王学院分期系统确定的临床进展之间的关联。方法：ALS患者于2008年5月至2016年12月登记。比较两组血清学指标的差异及其与疾病分期的相关性。结果：共纳入571例患者和571例年龄/性别/BMI匹配的健康对照。ALS患者血清肌酐、尿酸（UA）、白蛋白、总蛋白、总胆固醇、高密度脂蛋白（HDL）水平显著低于健康对照组，低密度脂蛋白/HDL比值显著高于健康对照组。UA、白蛋白、总蛋白水平与疾病分期呈显著负相关。对81例ALS患者的纵向观察也显示，UA、肌酐、白蛋白、总蛋白和HDL水平在第二次血液学检查中显著降低。结论：在本研究中，ALS患者和对照受试者在性别、年龄和BMI值方面均匀匹配，这一发现可以被认为是ALS中的代谢物特征。代谢物相关血清学因子随疾病分期的变化可能与疾病的病理生理有关，在临床上可能具有一定的应用价值。
Objective: Little is known whether disease clinical stage would influence the serological values in Amyotrophic lateral sclerosis (ALS). We aimed to explore the association between the levels of serological factors with clinical progression determined by the King's College staging system. Methods: ALS Patients were registered from May 2008 to December 2016. The differences of serological values between patients and healthy controls, and the correlation of these serological values with disease stage were examined. Results: A total of 571 patients and 571 age-/gender-/BMI-matched healthy controls were included. The levels of creatinine, uric acid (UA), albumin, total protein, total cholesterol, and high-density lipoprotein (HDL) were significantly lower, and the low-density lipoprotein/HDL ratio was higher in ALS patients than those in healthy controls. The levels of UA, albumin, and total protein were significantly reversely correlated with diseases stages. The longitudinal observation of 81 ALS patients also showed that the levels of UA, creatinine, albumin, total protein, and HDL were significantly decreased in the second hematological examinations. Conclusions: In the present study, ALS patients and control subjects were evenly matched with regard to sex, age, and BMI value, this finding could be considered as a metabolite signature in ALS. The changes of metabolite-based serological factors with progression of disease stage might be related to the pathophysiology of disease, and might have clinical utility in clinical practice.